2018 Metabolic Stability Regulations Treatment 
Metabolite Tales Blog
DECEMBER 13, 2023
The pyrazole in a drug compound developed by LEO as an oral IL-17A protein-protein interaction modulator for the treatment of psoriasis and other inflammatory disorders is susceptible to N -glucuronidation. A route to be avoided or a desired route of metabolism? Tukey, Ryoichi Fujiwara. PMID: 9733662. [8] Antimicrob Agents Chemother.
Metabolite Tales Blog
APRIL 4, 2023
3 Metabolism differences at steady state Adagrasib, Mirati’s irreversible KRASG12C inhibitor for treatment of non-small cell lung cancer is mainly metabolised by CYP3A4. Interestingly however, since adagrasib (MRTX849) inhibits CYP3A4 following multiple dosing, its metabolism is subsequently taken over by other CYPs.
Expert insights. Personalized for you.
59 
Let's personalize your content